French biotechnology startup Orakl Oncology raises €3M in Funding

Orakl Oncology leverages a unique collection of patient tumor avatars that combines biology and clinical data to fuel the therapeutic arsenal to fight cancer. With its platform it partners with oncology players to identify relevant targets and deliver new drugs, faster. Here are details of Orakl Oncology‘s latest funding round :

🚀 Launch

/

🏭 Industry

Biotechnology

🧠Management

Fanny Jaulin, PhD (CEO & CSO), Diane-Laure Pagès, PhD (COO), Gustave Ronteix, PhD (CTO)

💸 Funding & Investors

INVESTMENT (October 2023)€3 million
INVESTORS (October 2023)led by Speedinvest with additional investment from HCVC and Verve Ventures.

🎯 Funding purpose

Launch its wet and dry lab capabilities and to hire several key team members, including a Senior Oncology Scientist, Organoid Scientists, a Head of Lab, an Automation Engineer and an AI Research Scientist. This will enable Orakl Oncology to execute its first contracts with pharma and biotech partners.

🌐 Country HQ

France (Paris)

Leave a Reply

Your email address will not be published.